Spyre Therapeutics, Inc. Stock Analysis & AI Score
Spyre Therapeutics, Inc. (SYRE) has an ST Score of 51.9 (C+), driven by its Financial Strength (A+) and held back by its Growth (C-). Analysts rate it Buy with a $111.82 price target (+28.4% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Spyre Therapeutics, Inc. (SYRE) has an ST Score of 51.9 (C+), driven by its Financial Strength (A+) and held back by its Growth (C-). Analysts rate it Buy with a $111.82 price target (+28.4% upside).
- Strongest
- Financial StrengthA+
- Weakest
- GrowthC-
All factor grades
- Financial StrengthA+
- ProfitabilityA-
- MomentumB
- ValuationC
- ForecastC
- GrowthC-
- Piotroski2/9
Contact
SYRE stock: frequently asked questions
What is SYRE's ST Score?
Spyre Therapeutics, Inc. (SYRE) has an ST Score of 51.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SYRE a buy, hold, or sell?
Analysts rate SYRE a Buy, with a price target of $111.82 (+28.4% vs the current price). Our ST Score grades it C+ (51.9/100). The ST Score is a data-driven signal, not a recommendation.
What are SYRE's factor grades?
Valuation C, Profitability A-, Financial Strength A+, Momentum B, Growth C-, Forecast C.
What is SYRE's valuation grade?
Spyre Therapeutics, Inc. (SYRE) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SYRE's growth grade?
Spyre Therapeutics, Inc. (SYRE) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SYRE's profitability grade?
Spyre Therapeutics, Inc. (SYRE) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SYRE's financial strength grade?
Spyre Therapeutics, Inc. (SYRE) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SYRE?
The average analyst price target for Spyre Therapeutics, Inc. (SYRE) is $111.82 from 13 analysts, which is +28.4% versus the recent price of $87.09.
What is SYRE's Piotroski score?
Spyre Therapeutics, Inc. (SYRE) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.